| 0.3625 0.003 (0.69%) | 10-24 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.43 | 1-year : | 0.46 |
| Resists | First : | 0.37 | Second : | 0.4 |
| Pivot price | 0.35 |
|||
| Supports | First : | 0.32 | Second : | 0.27 |
| MAs | MA(5) : | 0.35 |
MA(20) : | 0.35  |
| MA(100) : | 0.4 |
MA(250) : | 0.5 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 56.6 |
D(3) : | 47.7 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 0.98 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VXRT ] has closed below upper band by 14.5%. Bollinger Bands are 74.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 61 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.37 - 0.37 | 0.37 - 0.37 |
| Low: | 0.35 - 0.35 | 0.35 - 0.35 |
| Close: | 0.36 - 0.36 | 0.36 - 0.37 |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Mon, 20 Oct 2025
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025 - GlobeNewswire
Mon, 20 Oct 2025
Improved immune responses to GI.1 & GII.4 — Vaxart Phase 1 oral norovirus pill presented at IDWeek - Stock Titan
Mon, 13 Oct 2025
Lobbying Update: $50,000 of VAXART INC. lobbying was just disclosed | VXRT Stock News - Quiver Quantitative
Wed, 08 Oct 2025
Vaxart, Inc. to Present Research on Norovirus and COVID-19 Oral Vaccine Programs at World Vaccine Congress Europe 2025 - Quiver Quantitative
Wed, 08 Oct 2025
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - GlobeNewswire
Wed, 13 Aug 2025
VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 229 (M) |
| Shares Float | 227 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 21,170 (K) |
| Shares Short P.Month | 14,350 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | -70.2 % |
| Operating Margin | -36.8 % |
| Return on Assets (ttm) | -25 % |
| Return on Equity (ttm) | -100.4 % |
| Qtrly Rev. Growth | 520.7 % |
| Gross Profit (p.s.) | -0.17 |
| Sales Per Share | 0.35 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | 48 (M) |
| PE Ratio | -1.58 |
| PEG Ratio | 0 |
| Price to Book value | 2.58 |
| Price to Sales | 1.02 |
| Price to Cash Flow | -2.24 |
| Dividend | 12.18 |
| Forward Dividend | 0 |
| Dividend Yield | 3362.7% |
| Dividend Pay Date | 2024-12-19 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|